Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 2, 2004, Pages 129-130

  Ho, Wai Khoon ^a   Hankey, Graeme J ^a,b   Eikelboom, John W ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR RISK; DRUG BLOOD LEVEL; HUMAN; LABORATORY TEST; LONG TERM CARE; NOTE; PRIORITY JOURNAL; RISK; RISK REDUCTION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT FAILURE;

ASPIRIN; DRUG RESISTANCE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK; TREATMENT FAILURE;

EID: 1642412978     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200403000-00003     Document Type: Note

References (21)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
2. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev 2003; 2:15-28.
3. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1:1710-1713.
4. Hankey GJ, Eikelboom JW. Is aspirin resistance a cause of aspirin treatment failure? BMJ 2004 (in press).
5. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:573-574.
6. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108:1191-1195.
7. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88:711-715.
8. Eikelboom JW, Hankey GJ. Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Med 2004 (in press).
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71:397-403.
10. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78:1003-1007.
11. Eikelboom JW, Hirsh J, Weite JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655.
12. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965.
13. Golaṅski J, Nocuń M, Rózalski M, Drygas W, Watała C. An in vitro model for detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis 2004; 15:xxx-xxx.
14. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 1994; 25:2331-2336.
15. Weber AA, Zimmerman KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance [Letter]. Lancet 1999; 353:900.
16. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schrör K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121:982-984.
17. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, et al. Assessment of platelet function assays. Am Heart J 1998; 135:S170-S178.
18. Feuring M, Haseroth K, Janson CP, Falkenstein E, Schmidt BMW, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyser (PFA-100). Int J Clin Pharmacol Ther 1999; 37:584-588.
19. Hézard N, Metz D, Nazeyrollas P, Droullé C, Potron G, Nguyen P. PFA-100™ and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002; 108:43-47.
20. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96:1109-1116.
21. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003; 108:37-42.